| 8.30 Delayed Data As of Jul 19 |  -0.07 / -0.84%Today’s Change | 3.92 Today|||52-Week Range 21.71 | -11.42% Year-to-Date |
| Will Karyopharm Therapeutics Continue to Surge Higher? Jul 09 / Zacks.com - Paid Partner Content | Karyopharm Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4... Jun 28 / GlobeNewswirePNW - Paid Partner Content |
| Previous close | 8.37 |
| Today’s open | 8.39 |
| Day’s range | 8.10 - 8.41 |
| Volume | 1,243,496 |
| Average volume (3 months) | 1,921,618 |
| Market cap | $505.2M |
| Earnings growth (last year) | -11.78% |
| Earnings growth (this year) | -19.85% |
| Earnings growth (next 5 years) | -49.42% |
| Revenue growth (last year) | +1,790.09% |
| P/E ratio | NM |
| Price/Sales | 17.54 |
| Price/Book | 2.76 |
| Today’s change | Today’s % change | |
|---|---|---|
| EOLSEvolus Inc | -0.87 | -4.38% |
| CTMXCytomX Therapeutics ... | -0.63 | -5.14% |
| GLYCGlycoMimetics Inc | -0.71 | -5.98% |
| MISTMilestone Pharmaceut... | +0.31 | +1.62% |
| Next reporting date | August 5, 2019 |
| EPS forecast (this quarter) | -$0.98 |
| Annual revenue (last year) | $30.3M |
| Annual profit (last year) | -$178.4M |
| Net profit margin | -588.10% |
Sector Health Technology |
Industry Biotechnology |
Chief Executive Officer & Director Michael G. Kauffman |
President & Chief Scientific Officer Sharon Shacham |
Corporate headquarters Newton, Massachusetts |
